Randomized open label controlled trial to study Safety and Effect of itolizumab (antiCD6) in Relapsing Remitting Multiple Sclerosis.

Trial Profile

Randomized open label controlled trial to study Safety and Effect of itolizumab (antiCD6) in Relapsing Remitting Multiple Sclerosis.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Itolizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 29 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top